Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

In this succinct late-breaking science interview, Investigator, Dr Marielle Scherrer-Crosbie (Hospital of the University of Pennsylvania, US) discusses the results from the STOP-CA trial (Massachusetts General Hospital). This randomized phase II trial aims to investigate whether atorvastatin, a commonly prescribed statin drug for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin and prevent heart failure.

The results presented at ACC.23 showed that among study participants with lymphoma being treated with anthracyclines, the prophylactic use of atorvastatin over 12 months was associated with a lower rate of cardiac systolic dysfunction.

Interview Questions:
1. What unmet need does the STOP-CA trial aim to address?
2. What is the existing evidence supporting the use of statins in this specific patient population?
3. What is the trial design, patient population, and outcome measures?
4. What are the key findings?
5. What are the implications for patient care?
6. What further research is needed?

Recorded on-site at ACC.23, New Orleans.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "ACC 23: Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial" передвинте ползунок вправо